S
Sandra J. Horning
Researcher at Genentech
Publications - 293
Citations - 30743
Sandra J. Horning is an academic researcher from Genentech. The author has contributed to research in topics: Lymphoma & Rituximab. The author has an hindex of 77, co-authored 293 publications receiving 29428 citations. Previous affiliations of Sandra J. Horning include New York University & University of California, Los Angeles.
Papers
More filters
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann,Edie Weller,Vicki A. Morrison,Randy D. Gascoyne,Peter A. Cassileth,Jeffrey B. Cohn,Shaker R. Dakhil,Bruce A. Woda,Richard I. Fisher,Bruce A. Peterson,Sandra J. Horning +10 more
TL;DR: Rituximab administered as induction or maintenance with CHOP chemotherapy significantly prolonged FFS in older DLBCL patients, which are consistent with an additive effect of ritUXimab.
Journal ArticleDOI
The natural history of initially untreated low-grade non-Hodgkin's lymphomas.
TL;DR: The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis, and the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.